CENPI identified as a promoter of hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway
CENPI is linked to hepatocellular carcinoma progression through activation of the PI3K/AKT/mTOR-CDK2 cascade.
Asset / Drug
Drug and asset intelligence for CENPI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.